FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.90), $0.20 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $44.32 million versus the consensus estimate of $34.73 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.